{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:11:27Z","timestamp":1777504287613,"version":"3.51.4"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CPD"],"published-print":{"date-parts":[[2013,4,1]]},"DOI":"10.2174\/13816128113199990313","type":"journal-article","created":{"date-parts":[[2013,4,8]],"date-time":"2013-04-08T03:27:12Z","timestamp":1365391632000},"page":"3161-3172","source":"Crossref","is-referenced-by-count":69,"title":["Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies"],"prefix":"10.2174","volume":"19","author":[{"given":"Nabil G.","family":"Seidah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/108708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T13:45:26Z","timestamp":1448027126000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/openurl\/content.php?genre=article&issn=1381-6128&volume=19&issue=17&spage=3161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,1]]},"references-count":0,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2013,4,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/13816128113199990313","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4,1]]}}}